


Claims:

Claims 1-14 (**canceled**)

15. **(currently amended)** A polypharmacophore represented by formula (II):



(II)

wherein:

R₁ is -CO₂R₄[[,] or -CO₂N(R₄)₂, ~~aryl, alkyl, aralkyl, or aralkenyl~~;

R₂ represents independently for each occurrence H, F, Cl, Br, or I, amino, azido, nitro, sulfonate, sulfonyl, cyano, hydroxyl, alkyl, aryl, heteroalkyl, heteroaryl, aralkyl, trialkylsilyl, or acyl;

R₃ represents independently for each occurrence H, F, Cl, Br, or I, amino, azido, nitro, sulfonate, sulfonyl, cyano, hydroxyl, alkyl, aryl, heteroalkyl, heteroaryl, aralkyl, trialkylsilyl, or acyl;

R₄ represents independently for each occurrence H[,,] or alkyl, aryl, alkenyl, alkynyl, heteroalkyl, or heteroaryl; and

the stereochemical configuration of the carbon-carbon double bond is Z, E, or a mixture of Z and E.

16. **(canceled)**

17. **(canceled)**

18. **(currently amended)** The polypharmacophore of claim 15, wherein said polypharmacophore is used to modulate A method of modulating the function of the dopaminergic system in a mammal, comprising the step of:

administering to a mammal in need thereof a therapeutically effective amount of a polypharmacophore of claim 15.

19. **(currently amended)** ~~The polypharmacophore of claim 15, wherein said polypharmacophore is used to treat diseases and conditions~~ A method of treating a disease or condition selected from the group consisting of Alzheimer's Disease, Huntington's Disease, depression, attention deficit disorder, autism, obesity and inflammation in a mammal; comprising the step of:

administering to a mammal in need thereof a therapeutically effective amount of a polypharmacophore of claim 15.

Claims 20-54 **(canceled)**


55. **(previously presented)** The polypharmacophore of claim 15, wherein R₂ is F.

56. **(previously presented)** The polypharmacophore of claim 15, wherein R₂ is F and R₃ is H.

57. **(previously presented)** The polypharmacophore of claim 15, wherein R₁ is CO₂R₄.

58. **(previously presented)** The polypharmacophore of claim 15, wherein R₁ is CO₂R₄ and R₄ is H.

59. **(previously presented)** The polypharmacophore of claim 15, wherein said compound is selected from group consisting of:



60. **(previously presented)** A pharmaceutical composition, comprising:

a polypharmacophore of claim 15, 55, 56, 57, 58 or 59, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier.